Q3 EPS Forecast for Sarepta Therapeutics Raised by Analyst

Key Points

• Analysts from Leerink Partners have raised their Q3 2025 earnings per share (EPS) forecast for Sarepta Therapeutics from ($1.08) to ($0.70), maintaining a "Hold" rating for the stock.
• Sarepta Therapeutics reported a significant quarterly revenue increase of 68.4% year-over-year, totaling $611.09 million, with earnings per share surpassing expectations at $2.02.
• Various analysts have mixed ratings on Sarepta Therapeutics, with eight recommending a Buy, fifteen a Hold, and six a Sell, indicating a generally cautious sentiment among investors.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for Sarepta Therapeutics in a report issued on Monday, September 8th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings per share of ($0.70) for the quarter, up from their prior estimate of ($1.08). Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.67 per share. Leerink Partnrs also issued estimates for Sarepta Therapeutics' Q4 2025 earnings at ($1.41) EPS, FY2025 earnings at ($3.99) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.69 EPS and FY2026 earnings at $2.91 EPS.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The firm had revenue of $611.09 million for the quarter, compared to the consensus estimate of $530.66 million. During the same period last year, the firm earned $0.07 earnings per share. The company's quarterly revenue was up 68.4% on a year-over-year basis.

Other equities research analysts also recently issued reports about the stock. Jefferies Financial Group lowered their target price on shares of Sarepta Therapeutics from $40.00 to $35.00 and set a "buy" rating for the company in a research note on Thursday, July 24th. Barclays upgraded shares of Sarepta Therapeutics from an "underweight" rating to an "equal weight" rating and set a $22.00 target price for the company in a research note on Tuesday, July 29th. Needham & Company LLC restated an "underperform" rating on shares of Sarepta Therapeutics in a research note on Monday, July 28th. Scotiabank upgraded shares of Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 target price for the company in a research note on Friday, June 6th. Finally, JPMorgan Chase & Co. upgraded shares of Sarepta Therapeutics from an "underweight" rating to a "neutral" rating and set a $24.00 target price for the company in a research note on Tuesday, July 29th. Eight research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $42.36.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $17.22 on Thursday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The firm's 50 day moving average price is $17.77 and its 200-day moving average price is $42.51. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $138.81. The company has a market cap of $1.68 billion, a PE ratio of -19.79 and a beta of 0.49.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in SRPT. Captrust Financial Advisors raised its holdings in shares of Sarepta Therapeutics by 15.4% during the fourth quarter. Captrust Financial Advisors now owns 4,468 shares of the biotechnology company's stock worth $543,000 after purchasing an additional 597 shares during the last quarter. Cetera Investment Advisers increased its holdings in Sarepta Therapeutics by 4.3% in the fourth quarter. Cetera Investment Advisers now owns 11,174 shares of the biotechnology company's stock valued at $1,359,000 after buying an additional 463 shares in the last quarter. Focus Partners Wealth increased its holdings in Sarepta Therapeutics by 30.0% in the fourth quarter. Focus Partners Wealth now owns 2,275 shares of the biotechnology company's stock valued at $277,000 after buying an additional 525 shares in the last quarter. Lighthouse Investment Partners LLC increased its holdings in Sarepta Therapeutics by 112.9% in the fourth quarter. Lighthouse Investment Partners LLC now owns 2,446 shares of the biotechnology company's stock valued at $297,000 after buying an additional 21,446 shares in the last quarter. Finally, Logan Capital Management Inc. purchased a new position in Sarepta Therapeutics in the fourth quarter valued at $61,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.